Subscribe to Search results

A product information sheet for the Scottish achievement recorded that it had ten times as much Factor 8 activity as fresh frozen plasma, and that "A similar fraction is prepared by ether fractionation (Kekwick)."

Published on:

An article "Red Cell Banking and the Production of a Factor VIII Concentrate" published in Vox Sanguinis demonstrated that by 1960, the Blood Products Unit in Edinburgh was fractionating plasma from 1,425 donors and investigating red cell concentrates to make full use of the donated blood.

Published on:

An article titled "A Concentrate of Human Antihaemophilic Factor - its use in six cases of haemophilia" published in The Lancet reported that they had developed antihaemophilic fraction ("AHF") which would enable clotting and had been used with success in six cases.

Published on:

In an article on "The Use of Human Anti-haemophilic Globulin (Fraction I-O) in Haemophilia A and in von Willebrand's Disease" published in Acta Haematologica, the development of antihaemophilic globulins (AHG) was reported which had treated 59 patients by 1959 in Sweden.

Published on:

The minutes of the meeting of the Joint Steering Committee on Blood Products Production recorded that planning to extend BPL had commenced in 1962, however building had only commenced in 1969. The extension of BPL had operated at capacity from April 1972, and the original buildings were also being modernised with the expectation they would be completed by August 1973.

Published on:

A letter from the SHHD to Dr Maycock addressed the question of how much plasma the Blood Products Unit in Edinburgh would fractionate for England and Wales.

Published on:

Dr Gunson and Dr Helen Dodsworth wrote "Fifty Years of Blood Transfusion" published in Transfusion Medicine which outlined the history of transfusion medicine in England and Wales.

Published on:

PFC first produced factor concentrates in January 1975, and reached full capability using "9 to 5" production in 1976.

Published on:

The Immuno Limited Table of Supply for Kryobulin and Bebulin 1969-1972 showed that Kryobulin was first used in the UK in 1970.

Published on:

Dr Biggs wrote to Professor Edward Blackburn regarding the problem of coming up with a 10-year estimate of how much blood would need to be collected in the UK. The subjectivity of clinical need, as well as the difference between "demand" and "need" for treatments meant that it was not easy to identify.

Published on:

A memo from Donald Jackson to Michael Lillywhite (DHSS) illustrated the difficulty of of providing an estimate for the level for production which would achieve self-sufficiency.

Published on:

John Watt wrote to Dr Rosemary Biggs expressing that one standard view at the time was that people with haemophilia needed to be able to live a normal sedentary lifestyle.

Published on:

There was always self-sufficiency in blood. London private hospitals would source blood from abroad and when they were over-provided, they would then pass their surplus to the NHS. Some patients in London would be given blood which was not necessarily tested in the same way as NHS blood would have been nor sourced from voluntary donors.

Published on:

Malcolm Widdup wrote to Andrew Mitchell to say more AHF/AHG was needed and Dr Bigg's view was convincing enough that the Treasury were prepared to fund preparations to meet it.

Published on:

England had a number of reference centres with haemophilia centres within their area. Oxford was the reference centre for the Alton Centre which served Treloar's school.

Published on:

Professor Blackburn wrote to Sir George Godber that directors felt an urgent need to increase supplies of Factor 8 concentrate because if British preparation could not be made available, commercial preparations should be bought.

Published on:

Dr Maycock wrote to Dr Reid that the UK should aim to be self-sufficient in the supply of preparations of anti-haemophilic globulin and Factor 9.

Published on:

Sir George Godber wrote to Sir Philip Rogers that due to increasing expenditure on commercial products being licenced there was a need to consider how far the home supply could be increased, leading to a lower cost.

Published on:

Sir George Godber wrote to Sir Philip Rogers that the expense of producing commercial or domestic concentrate was thought to be unavoidable in principle and providing domestic supplies would likely be cheaper than purchasing commercial concentrate.

Published on:

The initial aim was to supply concentrate made from 250,000 donations for use in home treatment, with the balance being cryoprecipitate.

Published on: